Sources close to the offering say the key selling points for the Chinese manufacturer of generic Western drugs will be its vertically integrated business model which gives it better control over product quality and production costs and also ensures higher margins versus most of its industry peers. It also has a well-recognised brand name, an extensive sales and marketing network and a strong pipeline of 26 new drugs that are expected to come to market...
¬ Haymarket Media Limited. All rights reserved.
